Odonate Therapeutics, Inc. (ODTC)

Odonate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cost of Revenue	0.02	0.34	1.05	0.87	0.38
Gross Profit	-0.02	-0.34	-1.05	-0.87	-0.38
Selling, General & Admin	0.8	3.58	9.29	10.39	10.9
Research & Development	0	0	36.48	117.04	104.03
Other Operating Expenses	0	0	0	1.08	0
Operating Expenses	0.8	3.58	45.77	127.43	114.93
Operating Income	-0.82	-3.92	-46.82	-127.43	-114.93
Interest Income	0	0	0	0	3.11
Other Expense / Income	-10.26	-13.56	21.49	-1.08	-
Pretax Income	9.44	9.64	-68.32	-126.35	-111.83
Income Tax	2.12	-33.3	0	0	-3.11
Net Income	7.33	42.94	-68.32	-126.35	-108.72
Net Income Growth	-82.94%	-	-	-	-
Shares Outstanding (Basic)	3	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0
Shares Change	98440.07%	-96.16%	15.40%	8.57%	23.78%
EPS (Basic)	2.56	14767.00	-900.72	-1922.40	-1795.96
EPS (Diluted)	2.55	14743.00	-900.72	-1922.40	-1795.96
EPS Growth	-99.98%	-	-	-	-
Free Cash Flow	8.74	1.8	-75.75	-113.56	-96.8
Free Cash Flow Per Share	3.05	616.30	-998.76	-1727.84	-1599.11
Effective Tax Rate	22.44%	-345.53%	-	-	-
EBITDA	-0.8	-3.58	-45.77	-126.99	-114.55
Depreciation & Amortization	0.02	0.34	1.05	0.45	0.38
EBIT	-0.82	-3.92	-46.82	-127.43	-114.93

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.